ID

22878

Descrizione

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00612794

collegamento

https://clinicaltrials.gov/show/NCT00612794

Keywords

versioni (1)
  1. 13/06/17 13/06/17 -
Caricato su

13 giugno 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes NCT00612794

Inglese

Eligibility Type 2 Diabetes NCT00612794

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
body weight ≥50 kg.
Descrizione

body weight

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005910
have suboptimal glycemic control as evidenced by an hba1c defined by the following criteria: *6.5% to 10.0%, inclusive, at study start for patients managed with diet modification and exercise or treated with oral antidiabetics drug but not alpha glucosidase inhibitor or meglitinide derivatives; *6.5% to 9.5%, inclusive, at study start for patients treated with oral antidiabetics including alpha glucosidase inhibitor or meglitinide derivatives.
Descrizione

suboptimal glycemic control, hba1c, diet modification and exercise or treated with oral antidiabetics, hba1c, oral antidiabetics including alpha glucosidase inhibitor or meglitinide

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0342299
UMLS CUI [2,1]
C0202054
UMLS CUI [2,2]
C0086153
UMLS CUI [2,3]
C0015259
UMLS CUI [2,4]
C0359086
UMLS CUI [3,1]
C0202054
UMLS CUI [3,2]
C0359086
UMLS CUI [3,3]
C0332257
UMLS CUI [3,4]
C1299007
UMLS CUI [3,5]
C0065880
have been treated with diet modification and exercise alone or in combination with a stable regimen of oral antidiabetic drugs (sulfonylurea, metformin and thiazolidinedione) for at least 2 months prior to study start.
Descrizione

diet modification and exercise, stable regimen of oral antidiabetic drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0086153
UMLS CUI [1,2]
C0015259
UMLS CUI [2,1]
C0359086
UMLS CUI [2,2]
C0205360
the patients with concomitant use of alpha glucosidase inhibitors (glucobay® [acarbose], basen® [voglibose], or seibule®[miglitol]) or meglitinide derivatives (glufast® [mitiglinide] or fastic®/starsis® [nateglinide]) can be included in this study, but these drugs must be discontinued after confirmation of eligibility at study start.
Descrizione

concomitant therapy with alpha glucosidase inhibitors or meglitinide derivatives, discontinuation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C1299007
UMLS CUI [1,3]
C0065880
UMLS CUI [1,4]
C4288399
in the case of patients with concomitant use of sulfonylurea, the dose of sulfonylurea must not be more than maximum recommended dose.
Descrizione

concomitant use of sulfonylurea, drug dose

Tipo di dati

text

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C3536898
UMLS CUI [1,3]
C0678766
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who have donated more than 200 ml of blood and component blood donation within one month of study start, or those who have donated more than 400 ml of blood within three months of study start.
Descrizione

blood donation, volume

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005794
UMLS CUI [1,2]
C0449468
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Descrizione

concomitant therapy, pharmaceutical preparations

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C0013227
have participated and received at least one dose of exenatide or other glp-1 analogs in this study previously, or any other study using exenatide or other glp-1 analogs.
Descrizione

exenatide, glp-1 analogs, study subject participation status

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0167117
UMLS CUI [1,2]
C3273809
UMLS CUI [1,3]
C2348568
are treated with any exogenous insulin within 3 months of screening.
Descrizione

exogenous insulin

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0205228
UMLS CUI [1,2]
C0745343
are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): *drugs that directly affect gastrointestinal motility, including nauzelin® (domperidone), primperan®/terperan® (metoclopramide), ganaton® (itopride), acenalin® (cisapride), gasmotin® (mosapride), or cerekinon® (trimebutine).
Descrizione

drugs that directly affect gastrointestinal motility, Domperidone; Metoclopramide; itopride; Cisapride; mosapride; Trimebutine

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0017184
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C0013015
UMLS CUI [1,4]
C0025853
UMLS CUI [1,5]
C0531483
UMLS CUI [1,6]
C0072916
UMLS CUI [1,7]
C0526501
UMLS CUI [1,8]
C0041023
females who are breastfeeding.
Descrizione

breastfeeding, gender

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0006147
UMLS CUI [1,2]
C0079399
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes NCT00612794

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
body weight
Item
body weight ≥50 kg.
boolean
C0005910 (UMLS CUI [1])
suboptimal glycemic control, hba1c, diet modification and exercise or treated with oral antidiabetics, hba1c, oral antidiabetics including alpha glucosidase inhibitor or meglitinide
Item
have suboptimal glycemic control as evidenced by an hba1c defined by the following criteria: *6.5% to 10.0%, inclusive, at study start for patients managed with diet modification and exercise or treated with oral antidiabetics drug but not alpha glucosidase inhibitor or meglitinide derivatives; *6.5% to 9.5%, inclusive, at study start for patients treated with oral antidiabetics including alpha glucosidase inhibitor or meglitinide derivatives.
boolean
C0342299 (UMLS CUI [1])
C0202054 (UMLS CUI [2,1])
C0086153 (UMLS CUI [2,2])
C0015259 (UMLS CUI [2,3])
C0359086 (UMLS CUI [2,4])
C0202054 (UMLS CUI [3,1])
C0359086 (UMLS CUI [3,2])
C0332257 (UMLS CUI [3,3])
C1299007 (UMLS CUI [3,4])
C0065880 (UMLS CUI [3,5])
diet modification and exercise, stable regimen of oral antidiabetic drugs
Item
have been treated with diet modification and exercise alone or in combination with a stable regimen of oral antidiabetic drugs (sulfonylurea, metformin and thiazolidinedione) for at least 2 months prior to study start.
boolean
C0086153 (UMLS CUI [1,1])
C0015259 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
concomitant therapy with alpha glucosidase inhibitors or meglitinide derivatives, discontinuation
Item
the patients with concomitant use of alpha glucosidase inhibitors (glucobay® [acarbose], basen® [voglibose], or seibule®[miglitol]) or meglitinide derivatives (glufast® [mitiglinide] or fastic®/starsis® [nateglinide]) can be included in this study, but these drugs must be discontinued after confirmation of eligibility at study start.
boolean
C1707479 (UMLS CUI [1,1])
C1299007 (UMLS CUI [1,2])
C0065880 (UMLS CUI [1,3])
C4288399 (UMLS CUI [1,4])
concomitant use of sulfonylurea, drug dose
Item
in the case of patients with concomitant use of sulfonylurea, the dose of sulfonylurea must not be more than maximum recommended dose.
text
C1707479 (UMLS CUI [1,1])
C3536898 (UMLS CUI [1,2])
C0678766 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
blood donation, volume
Item
subjects who have donated more than 200 ml of blood and component blood donation within one month of study start, or those who have donated more than 400 ml of blood within three months of study start.
boolean
C0005794 (UMLS CUI [1,1])
C0449468 (UMLS CUI [1,2])
concomitant therapy, pharmaceutical preparations
Item
have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C1707479 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
exenatide, glp-1 analogs, study subject participation status
Item
have participated and received at least one dose of exenatide or other glp-1 analogs in this study previously, or any other study using exenatide or other glp-1 analogs.
boolean
C0167117 (UMLS CUI [1,1])
C3273809 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
exogenous insulin
Item
are treated with any exogenous insulin within 3 months of screening.
boolean
C0205228 (UMLS CUI [1,1])
C0745343 (UMLS CUI [1,2])
drugs that directly affect gastrointestinal motility, Domperidone; Metoclopramide; itopride; Cisapride; mosapride; Trimebutine
Item
are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): *drugs that directly affect gastrointestinal motility, including nauzelin® (domperidone), primperan®/terperan® (metoclopramide), ganaton® (itopride), acenalin® (cisapride), gasmotin® (mosapride), or cerekinon® (trimebutine).
boolean
C0017184 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0013015 (UMLS CUI [1,3])
C0025853 (UMLS CUI [1,4])
C0531483 (UMLS CUI [1,5])
C0072916 (UMLS CUI [1,6])
C0526501 (UMLS CUI [1,7])
C0041023 (UMLS CUI [1,8])
breastfeeding, gender
Item
females who are breastfeeding.
boolean
C0006147 (UMLS CUI [1,1])
C0079399 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial